Table 2 Characteristics of participants evaluated for chloroquine and lumefantrine ex vivo susceptibility assay
| Characteristic | 2013 (N = 18) | 2014 (N = 49) | 2015 (N = 69) | 2016 (N = 24) | 2017 (N = 70) | 2018 (N = 33) |
|---|---|---|---|---|---|---|
| Median age, years (IQR) | 5.0 (2.3, 7.3) | 3.4 (2.0, 5.8) | 4.6 (2.4, 4.8) | 3.1 (2.0, 5.5) | 2.5 (1.1, 3.8) | 3.5 (1.0, 4.7) |
| Gender (male/female) | 8/10 | 28/21 | 30/38 | 14/10 | 33/37 | 17/16 |
| Clinical findings (n, %) | ||||||
| Muscle or joint aches | ND | 3 (6.1) | 3 (4.4) | 2 (8.3) | 1 (1.4) | 3 (9.1) |
| Headache | ND | 6 (12.2) | 8 (11.6) | 3 (12.5) | 5 (7.1) | 8 (24.2) |
| Anorexia | ND | 11 (22.5) | 7 (10.1) | 1 (4.2) | 5 (7.1) | 12 (36.4) |
| Nausea/vomiting | ND | 9 (18.4) | 17 (24.6) | 11 (45.8) | 20 (28.6) | 17 (51.5) |
| Abdominal pain | ND | 6 (12.2) | 7 (10.1) | 0 | 3 (4.3) | 0 |
| Diarrhoea | ND | 5 (10.2) | 6 (8.7) | 5 (21.0) | 7 (10.0) | 5 (15.2) |
| Cough | ND | 18 (37.0) | 10 (14.5) | 6 (25.0) | 21 (30.0) | 28 (84.9) |
| Convulsions | ND | 1 (2.0) | 1 (1.5) | 2 (8.3) | 3 (4.3) | 2 (6.1) |
| Jaundice | ND | 2 (4.1) | 0 | 0 | 0 | 0 |
| Temperature, °C (IQR) | 37.8 (37.4, 38.6) | 38.1 (37.2, 39.0) | 38.0 (37.5, 39.0) | 37.7 (37.5, 39.3) | 38.8 (37.8, 39.4) | 38.5 (37.9, 38.9) |
| Laboratory findings | ||||||
| Haemoglobin, g/dL (Range) | ND | 10.6 (6.3–13.1) | ND | ND | 12.7 (11.2–14.1) | 10.5 (9.3–11.6) |
| Parasitaemia*, % (IQR) | 0.2 (0.1, 0.5) | 1.0 (0.2, 2.6) | 2.1 (0.7, 4.8) | 2.1 (1.3, 3.3) | 3.5 (2.4, 6.0) | 2.0 (1.5, 2.8) |
